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Abstract
Study Objectives
Sleep reduction after stroke is linked to poor recovery in patients. Conversely, a neuropro-
tective effect is observed in animals subjected to acute sleep deprivation (SD) before ische-
mia. This neuroprotection is associated with an increase of the sleep, melanin concentrating
hormone (MCH) and orexin/hypocretin (OX) systems. This study aims to 1) assess the rela-
tionship between sleep and recovery; 2) test the association between MCH and OX systems
with the pathological mechanisms of stroke.
Methods
Sprague-Dawley rats were assigned to four experimental groups: (i) SD_IS: SD performed
before ischemia; (ii) IS: ischemia; (iii) SD_Sham: SD performed before sham surgery; (iv)
Sham: sham surgery. EEG and EMG were recorded. The time-course of the MCH and OX
gene expression was measured at 4, 12, 24 hours and 3, 4, 7 days following ischemic sur-
gery by qRT-PCR.
Results
A reduction of infarct volume was observed in the SD_IS group, which correlated with an
increase of REM sleep observed during the acute phase of stroke. Conversely, the IS group
showed a reduction of REM sleep. Furthermore, ischemia induces an increase of MCH and
OX systems during the acute phase of stroke, although, both systems were still increased
for a long period of time only in the SD_IS group.
Conclusions
Our data indicates that REM sleep may be involved in the neuroprotective effect of SD pre-
ischemia, and that both MCH and OX systems were increased during the acute phase of
PLOS ONE | DOI:10.1371/journal.pone.0168430 January 6, 2017 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Pace M, Adamantidis A, Facchin L,
Bassetti C (2017) Role of REM Sleep, Melanin
Concentrating Hormone and Orexin/Hypocretin
Systems in the Sleep Deprivation Pre-Ischemia.
PLoS ONE 12(1): e0168430. doi:10.1371/journal.
pone.0168430
Editor: Eric Murillo-Rodriguez, Universidad
Anahuac Mayab, MEXICO
Received: July 23, 2016
Accepted: December 1, 2016
Published: January 6, 2017
Copyright: © 2017 Pace et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: 3Vo, three-vessel occlusion
method of ischemic stroke; CCA, Common Carotid
s
o
u
r
c
e
:
 
ht
tp
:/
/b
or
is
.u
ni
be
.c
h/
93
28
3/
 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
stroke. Future studies should assess the role of REM sleep as a prognostic marker, and test
MCH and OXA agonists as new treatment options in the acute phase of stroke.
Introduction
Ischemic stroke is one of the major causes of death and permanent disability worldwide [1, 2].
Recombinant tissue-type plasminogen (rtPA) is the standard treatment for acute ischemic
stroke [3]. However, even if randomized trials have demonstrated that more patients show
good outcomes in 50–70% of cases when treated with rtPA [4, 5], this therapy, unfortunately,
is only available to less than 10% of the patients [6], due to the narrow therapeutic window
(<4.5 h) and the increased risk of intracranial haemorrhage [5].
These limitations have emphasized the need for alternative therapies. Most of these thera-
peutic approaches have focused on protecting neurons from the main pathogenic mechanisms
causing ischemic injury, such as excitotoxicity, oxidative stress, inflammation or apoptosis [7].
These neuroprotective agents have shown good results in animal models, however, when they
have been tested on humans they have failed dramatically [8].
Current efforts to find alternative therapies are working towards understanding the brain’s
endogenous protective mechanisms [9], including preconditioning. Preconditioning is a pro-
cedure by which a noxious stimulus, near to but below the damage threshold, induces an adap-
tive response that protects against subsequent ischemia [10].
Several stimuli have been used as preconditioning before ischemia including total sleep
deprivation (SD pre-ischemia). In fact, it has been observed that SD pre-ischemia confers pro-
tection against subsequent ischemic damage by significantly reducing infarct volume after 7
days from ischemic stroke [11, 12]. Moreover, significant reductions in inflammatory response
and apoptotic processes that strongly and negatively affect stroke outcome were observed [13,
14]. Additionally, our group had previously observed that SD pre-ischemia animals showed a
significant increase in the amount of total sleep during the first 24h following ischemia. This
suggests that the increase in the total amount of sleep during the acute phase of stroke posi-
tively modulates functional recovery [11]. Consistent with the hypothesis that sleep is essential
for functional recovery, pharmacological enhancement of slow wave sleep after ischemia
showed a positive outcome in animal models of stroke [15, 16].
Sleep-reduction/fragmentation is very common after ischemic stroke, affecting at least,
20% to 40% of stroke patients, and is linked with poor functional outcomes [17–20]. These
sleep disturbances following ischemic stroke may involve both stages of sleep, rapid eye move-
ment (REM) and non-rapid eye movement (non-REM) [17]. Particularly, the reduction of
REM sleep has been associated with negative functional recovery [21, 22]. Conversely, a recent
study conducted on chronic ischemic stroke patients showed that the more time the patient
spent in REM sleep, the more offline motor learning increases [23]. However, the specific role
of REM sleep on ischemic stroke, and how it may affect patient outcomes remains unknown.
A recent study published by our group [24] observed an increase of two genes, melanin-
concentrating hormone (MCH) and Orexin/Hypocretin (OX), (see Box 1 on Physiological
roles of OX and MCH neurons), in SD pre-ischemia animals and not in ischemia animals
alone after 3 days from ischemia. A body of evidence has already shown an early involvement
of OXA in the pathophysiology following ischemic stroke by identifying several mechanisms
of action [25–27]. However, to date the involvement of MCH and OX in the neuroprotective
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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effect elicited by SD is elusive; this study describes for the first time a possible role or associa-
tion between MCH and ischemic stroke.
This study aims firstly at defining the role of REM sleep on stroke, and if REM sleep corre-
lates with positive outcomes after ischemic stroke, and thus, if it may be used as a prognostic
marker. The second aim is to investigate if both the MCH and OX systems are associated with
the pathophysiology of stroke and with the beneficial effect elicited by SD. To test the associa-
tion, a time course of the expression of genes related to these systems was performed. Finally,
as MCH and OX systems are involved in the regulation of the sleep-wake cycle, although in
opposite ways, we aim to understand whether the expression of genes related to these systems
following ischemia are particularly tied to the sleep-wake cycle.
Materials and Methods
Male Sprague-Dawley rats (n = 112), 9–11 weeks old and weighing 300 ± 50 g at the time of
surgery, were used in this study. They were housed under 12-h light/dark cycle (light on
BOX 1. Physiological roles of Orexin/hypocretin (OX) and Melanin-
Concentrating Hormone (MCH) neurons
Neurons containing OX or MCH are mainly localised in the lateral hypothalamus. Each
constitutes a separate and distinct neuronal population, even if they project to similar tar-
get areas in the brain according to their respective receptors [64–67]. The main differ-
ences and similarities between these two neuropeptides are briefly discussed below OX
neurons synthetize two different neuropeptides: Orexin/hypocretin-A (OXA) and
Orexin/hypocretin-B (OXB). OX effects are mediated by two subtypes of OX receptors,
which are OX Recepor-1 (OX1R) and OX Recepor-2 (OX2R) that are differently
expressed in the brain. Particularly, OXA may satisfy its physiological functions by bind-
ing both OX1R and OX2R, whereas OX-B signals mainly act through OX2R [68]. Physio-
logical functions of the OX peptides include the stabilization of wakefulness [69, 70],
energy expenditure [71], behavioural responses to food reward and addiction [72], and
lastly increase food intake. It has also been observed that OXA release is stimulated by
low glucose and inhibited by high glucose [73]. Finally, it has been shown that OXA is
involved in the regulation of cardiovascular responses [74] and thermoregulatory systems
[71], as well as inflammation, suggesting an anti-inflammatory function in neuro-inflam-
mation diseases [62] and also inhibits apoptosis [61]. Recently, a consistent body of evi-
dence has highlighted a possible neuroprotective role of OXA in ischemic stroke by either
modulating inflammation [27] or modulating post-ischemic glucose intolerance [25, 75].
MCH exerts its action through the MCH1 receptor (Mchr1) and MCH2 receptor
(Mch R2), although the latter is not functional in rodents [76, 77]. As widely described,
MCH works in a complementary or even opposite manner to OX. Notably, MCH neu-
rons play opposing roles in the regulation of sleep-wake cycle. Indeed, MCH promotes
sleep, particularly MCH neurons fire during REM sleep [78]. In contrast to OX, MCH
promotes energy conservation and the activation of MCH neurons are regulated by ele-
vated glucose levels [79]. Finally, MCH supports depression and anxiety, while OX
increases the reinforcing properties of ingested substances [80]. However, MCH, as well
as OX, are orexigenic peptide, meaning that both stimulate food intake and promote the
consumption of palatable or caloric food [80].
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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08:00–20:00) with ambient temperature at 22 ± 0.5˚C. Food and water were provided ad libi-
tum. All animal procedures were approved by the Animal Research Committee and the Veteri-
nary Office of the Canton of Bern, Switzerland.
Experimental design
Rats were randomly assigned to the following experimental groups: (i) sleep deprivation
followed by ischemia (SD_IS); (ii) ischemia (IS); and (iii) sham surgery (Sham). Each experi-
mental group comprised 6 animals, which were sacrificed at several time points following
ischemia: 4; 12; and 24 hours (acute phase) and 3, 5 and 7 days (chronic phase), (Fig 1A). Over-
all, 18 animals were analysed at each time point except at 3 days, when an additional experi-
mental group underwent sleep deprivation followed by sham surgery (SD_Sham n = 4).
SD_Sham group was added only to assess the effect of SD over a longer period of time.
Sleep deprivation procedures
Total sleep deprivation was performed by gentle handling techniques, consisting of introduc-
ing novel objects into the cage, knocking or shaking the cage when behavioral signs of sleep
were observed. Animals were subjected to SD during the last 6h of the light period, and ische-
mia/sham surgery was performed immediately after, at the beginning of the dark period (Fig
1C) as previously described [11, 12]. Polysomnographic recordings were performed during the
whole period of total SD.
Surgical procedures
Implantation of EEG and EMG electrodes. Rats were anesthetized with 1.5%–2.5% iso-
flurane in oxygen and surgically implanted with electroencephalogram/electromyogram
(EEG/EMG) electrodes for sleep-wake recording. Mini-screw electrodes were implanted bilat-
erally in the parietal cortex (coordinates: 2 mm posterior of the bregma and 4.5 mm lateral to
the midline in the left and right parietal skull) and cerebellar cortex (coordinates: 2 mm poste-
rior of the lambda and 2 mm lateral to the midline in the left and right frontal skull) (Fig 1D).
EMG was recorded by 2 stainless steel wires inserted bilaterally into the neck muscles (Fig 1D).
Following surgery, all animals received paracetamol (200 mg/kg; twice a day; PO; Tempra)
and enrofloxacine (10mg/kg; once a day; SC; Baytril) for three days after surgery. Animals
were housed individually in their home cages for a recovery period of 4 days, and then each rat
was connected to a flexible cable and swivel (Plastics One) that allowed free movement within
the chambers, and habituated for 3 days with a cable, before EEG/EMG recording (Fig 1B and
S1 Fig). Rats were recorded continuously for 24 h for a baseline (12h:12h dark-light cycle), 6h
during total SD, and over the time until animals were sacrificed (Fig 1A and 1B). Notably
EEG/EMG recording was not performed during either the sham or stroke surgery.
Ischemic stroke surgery. Stroke was induced by the three-vessel occlusion method (3Vo)
[28], which predominantly affects the primary somatosensory cortex, avoiding thalamic, hypo-
thalamic, hippocampal, and midbrain damage [29]. We used this model because the relative
infarct volume in relation to brain size corresponds to the majority of human strokes. More-
over, this is a reproducible model with low mortality. 3Vo consists of the permanent occlusion
of the distal middle cerebral artery (MCA) and the ipsilateral common carotid artery (iCCA),
whereas the contralateral CCA (cCCA) was transiently occluded for 60 min with an aneurysm
clip. Stroke surgery was performed under general anesthesia with 2% isoflurane in oxygen.
A small piece of skull overlying the MCA was removed and the dura mater was retracted.
The MCA and its three main branches were occluded by bipolar electro coagulation. Body
temperature was maintained between 36.5±0.5˚C by a heating pad. Sham-operated rats were
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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subjected to the same procedure as well as the same time exposure for anaesthesia (approxi-
mately 90 minutes) except for the occlusion of the MCA and the CCA. After surgery rats were
returned to their cages and EEG/EMG were resumed until the end of the experiment (for time
points see Fig 1). To assess animal health and body condition, all animals were monitored
until the end of the experiment for the following parameters: body weight chenges, appetite,
gait, posture and attitude (i.e bright, alert, responsive or burrowing or hiding, quiet but rouses
when touched and finally, no cage exploration when lid off, burrows/hides, may vocalize or be
unusually aggressive when touched).
Fig 1. Schematic of the experiment design. (A) Design for the sleep architecture analysis and for the time
course of gene expression of MCH and OX systems. Ischemia surgery was performed on day 0, and then the
rats were sacrificed at 4, 12 and 24 hours (acute phase) and 3, 4 and 7 days (chronic phase) following
ischemic surgery. Baseline was recorded 2 days before ischemia for 24h; 12h dark and 12h light. Rats
subjected to SD were also recorded over 6h of SD. The EEG/EMG recordings were stopped when animals
were sacrificed; represented by each time point (B) Design for sleep architecture. Rats were implanted with
EEG/EMG electrodes and then allowed to recover for 4 days, and then connected to a flexible cable and
swivel and habituated for 3 days with a cable, before EEG/EMG recording. C) Design for SD interventions. SD
was performed by gentle handling during the last 6 h of the light period; from 14:00 to 20:00. And ischemia/
sham surgery was performed immediately after; at the beginning of the dark period, during either stroke or
sham surgery EEG/EMG recordings were not performed (D) Not-to-scale representation of the placement of
the screw electrodes over the parietal cortex and the cerebellar cortex (dark circles), Ref. = reference and
Gnd = ground. EMG was bilaterally placed in the neck muscle using wire electrodes (E) An anesthetized rat
fixed to the stereotaxic frame with EEG/EMG plug fixed to the skull with dental cement. Experimental groups:
i. SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv Sham (n = 6). Electroencephalogram (EEG);
Electromyogram (EMG).
doi:10.1371/journal.pone.0168430.g001
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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Electrophysiological data analysis
The EEG/EMG signals were amplified (Grass Instruments, USA), and digitized at a sampling
rate of 100 Hz and collected on a PC using VitalRecorder (Kissei Comtec Co. Ltd, Japan). EEG
signals were filtered at 0.3 Hz (low pass filter) and 0.1 KHz (high pass filter), respectively,
whereas EMG, at 1000 Hz. The polysomnographic recordings were visually scored offline-
using SleepSign software (Kissei Comtec Co. Ltd, Japan), per 10 second epoch window, as
wakefulness, non-REM sleep or REM sleep as previously described [11]. Scoring was per-
formed by a single observer, blinded to rat identity. The percentage of time spent in wakeful-
ness, non-REM and REM was determined for each hour. The total number and length
(seconds) of REM sleep bouts were assessed across the 24h of baseline and for the following
three days after ischemic stroke. REM sleep bout numbers were counted as each continuous
episode of the REM sleep state. REM sleep bout length was calculated by the amount of time
spent in separate bouts. Two EEG signals come from ipsilateral and contralateral hemispheres
to the lesion and muscle (EMG) were recorded, although, the behavioral states were scored
using the contralateral hemisphere (healthy hemisphere). However, when the signal was
unclear, affected by artefact movement or electrical noise, the recordings from the ipsilateral
hemisphere were consulted, and eventually tagged and excluded from subsequent analyses.
Polysomnographic recordings started immediately after ischemic or sham surgery, although
the analysis of the first 30/40 minutes was excluded because unusual spikes due to isoflurane
anaesthesia were observed in all animals.
Brain collection and infarct volume evaluation
At the end of the experiment, rats were decapitated while deeply anesthetized (Isoflurane 5%)
and brains dissected and frozen immediately in dry ice. For infarct volume evaluation, coronal
sections of 20 μm were cut on a cryostat at six predefined levels (L) with 1 mm interval (L-1:
2.7 mm; L-2: 1.7 mm; L-3: 0.7 mm; L-4: −0.3 mm; L-5: −1.3 mm and L-6: −2.3 mm from
bregma) and stained with cresyl violet and digitized [30, 31]. The remaining tissue between
these sections was cut at 50 μm and ischemic and contralateral hemispheres collected sepa-
rately and stored at −80˚C for gene expression analysis. The infarct area was measured for
each level by the public-domain ImageJ program (http://imagej.nih.gov/ij). All photographs
were analysed by two independent observers blinded to rat identity. Correction of the infarct
volume for edema was first calculated by subtracting the size of the undamaged area in the
stroke hemisphere from that in the intact hemisphere and then converted with the known dis-
tance between each level.
Gene expression analysis by quantitative real-time polymerase chain
reaction (qRT-PCR)
RNA was isolated separately from the ischemic and contralateral hemispheres from the 50 μm
sections by the Trizol method (Sigma Aldrich, Midtown-St Louis, MO, USA) according to the
manufacturer’s instruction [32]. RNA concentration was then determined by a NanoDrop
2000c spectrophotometer. The complementary DNA was obtained from up to 2 mg of total
RNA by using a high-capacity RNA-to-cDNA kit (Invitrogen) and stored at -20 C˚. TaqMan
Gene Expression Assay (Life Technologies, Carlsbad, CA, USA) was used to analyse the gene
expression of the MCH-system and OX-system. Notably, the analysis of the MCH-system
included the assessment of the precursor of MCH (Pmch) and its receptor MCH receptor 1
(Mchr1). Whereas, the analysis of the OX-system comprised the assessment of OX-A (OxA)
since it has been already observed to play a role in post-ischemic stroke and its two receptors,
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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OX receptor-1 (Ox1R) and OX receptor-2 Ox2R (see Table 1 for TaqMan assay references
sequencing). Additionally, we investigated the gene expression of brain-derived neurotrophic
factor (Bdnf) since it is involved in neuroplasticity and neurogenesis process [33]. Reactions
were performed in triplicate using AB 7900HT fast real-time PCR system (Applied Biosystems).
The relative level of mRNA was calculated as follows: mRNA = 2(-ΔCT experiment rat−ΔCT sham rat),
where ΔCT = (CT. target−CT. Gapdh) [15].
Statistical analysis
Gaussian distribution of values was tested with homogeneous variance (Levene test). Data
were presented as mean ± standard error of the mean (SEM). Infarct volume was assessed by
unpaired t-test. Sleep architecture across the acute phase was tested by paired t-test. Sleep
changes over the sub-acute and chronic phase after interventions was evaluated by repeated
measures ANOVA, whereas two-way ANOVA (factors: group and time) was used for analys-
ing REM sleep bouts. Gene expression across groups at several time points was assessed by
one-way ANOVA. Whenever ANOVA statistical significance was achieved, Tukey’s multiple
post hoc contrasts were performed to determine group-wise comparison. Pearson correlation
was performed in order to assess a link between the percentage of REM sleep across the acute
phase after stroke and the infarct volume assessed after 7 days from stroke. GraphPad Prism6
(GraphPad Prism Software, Inc) was used for statistical analysis. Type I error α was set at 0.05
(p< 0.05).
Results
Infarct volume analysis
In order to confirm the neuroprotective effect of SD pre-ischemia, infarct size was evaluated in
both IS and SD_IS groups at several time points: 12h, 24 h, 3, 4 and 7 days following experi-
mental ischemia. Animals subjected to sham surgery did not reveal any brain lesions.
SD_IS group showed a significant reduction in infarct volume at 12h (SD_IS: 35.62 ± 5.68
vs. IS: 75.27 ± 6.92 mm3; t(10) = 4.42, p = .001), 5 days (SD_IS: 28.4 ± 2.77 vs. IS: 92.52 ± 5.95
mm3; t(10) = 9.75, p = .0001) and 7 days (SD_IS: 48.65 ± 9.74 vs. IS: 96.66 ± 7.19 mm3; t(10) =
4.42, p = .002, Fig 2B) following ischemia. No significant reduction in infarct volume was
observed at 24h (SD_IS: 81.25 ± 6.37 vs. IS: 95.10 ± 8.12 mm3, t(10) = 1.34, p = .20) and at 3
days (SD_IS: 70.35 ± 5.33 vs. IS: 77.79 ± 5.23 mm3, t(10) = 0.99, p = .34, Fig 2B) following
ischemia. At 4h infarct volume was not assessed because the ischemic lesion was not evident
by cresyl violet staining.
Table 1. List of Taqman assays used for the qRT-PCR analysis.
Gene RefSeq
Gapdh (Glyceraldehyde 3-phosphate dehydrogenase used as endogenous control) Rn01775763_g1
Pmch (Precursor of melanin concentrating hormone (MCH)) Rn00561766_g1
Mchr1 (MCH receptor 1) Rn00755896_m1
Oxa (Orexin (OX)-A/Hypocretin 1) Rn00565995_m1
Ox1R (OX receptor 1) Rn00565032_m1
Ox2R (OX receptor 2) Rn00565155_m1
Bdnf (Brain-derived neurotrophic factor) Rn02531967_s1
doi:10.1371/journal.pone.0168430.t001
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Sleep-wake cycle architecture
Sleep EEG at the baseline. At the baseline (BL) recordings we did not observe any statisti-
cal differences concerning the circadian distribution of sleep between animals that were subse-
quently randomly divided into the four experimental groups: IS (n = 6); SD_IS (n = 6); Sham
(n = 6) and SD_sham (n = 4) groups. For sleep EEG analysis animals sacrificed at 7 days were
analysed, except for the latter group where animals sacrificed at 3 days were used. To make
correct comparisons respect to the control group (SD-Sham) sleep EEG changes were investi-
gated till 3 days after interventions. Data pooled from the 4 experimental groups shows an
increase in sleep time at BL during the light period of the light/dark cycle: animals slept for
approximately 57% of the recorded 12 hours (non-REM sleep: 47.65% ± 1,57%; REM sleep:
10.10% ± 0.37%) and approximately 22% during the dark period (non-REM sleep: 16.53% ±
0,81%; REM sleep: 5.46% ± 0.38%). Animals that were subjected to SD interventions (SD_IS
and SD_Sham) were kept awake for approximately 99.71% ± 0.50% of the 6h-sleep deprivation
procedure (non-REM sleep: 0.29% ± 0.50%; REM sleep:0%).
Changes in sleep EEG during the first 24h after interventions. During the first 24 hours
(acute phase) of either stroke or sham surgery the changes in the amount of total sleep (includ-
ing both non-REM and REM sleep) showed a significant increase exclusively in animals sub-
jected to SD interventions compared to their baseline across the 12h:12h dark-light cycle.
Indeed an increase of 15–20% in the amount of total sleep was observed in both groups SD_IS
(BL: 37.53% ± 2.88% vs. post-surgery: 55.29% ± 3.90% mm, t(5) = 3.59, p = .01) and in the
SD_Sham groups (BL: 40.45% ± 1.53% vs. post-surgery: 53.60% ± 1.74% t(3) = 3.58 p = .0009,
Fig 3B).
Fig 2. Effects of sleep deprivation (SD) pre-ischemia on the infarct volume. Lesion volumes corrected for edema were calculated by cresyl violet
staining at 12 and 24 hours and 3, 5 and 7 days after ischemic surgery are displayed on the x-axis (see S2 Fig for infarct volume assessed without edema
correction and S1 and S2 Tables for data set). (A) Representative sets of brain sections from a rat subjected to 6h of SD pre-ischemia (left panel), and
rats subjected to ischemia without SD (right panel). The infarct areas are delineated by a thin black line. L1 is at 2.7 mm anterior to bregma, and the
interval between each level is 1 mm (see methods). (B) Infarct volume (mean ± SEM) assessed at 12 and 24 hours and 3, 5 and 7 days after interventions
(n = 6 per group) were analysed by unpaired t-test. Dots represent infarct volume of each animal during each time points. Asterisks (*) indicate a
statistical difference between groups, **p .01; *** p .001.
doi:10.1371/journal.pone.0168430.g002
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During the dark period that immediately followed surgery (i.e. active phase in rats), the per-
centage of non-REM sleep was significantly increased (SD_IS p = .0001; IS p = .001; SD_Sham:
p = .03; Sham p = .0009, Fig 3C), whereas the amount of wakefulness (SD_IS p = .0001; IS;
SD_Sham: p = .004; Sham p = .01, Fig 3C) was significantly decreased in all conditions when
compared to their baseline. REM sleep was significantly increased only in the two groups sub-
jected to SD (SD_IS p = .02; SD_Sham: p = .04, respectively), whereas the IS and sham groups
did not differ compared to the baseline (Fig 3C).
During the light period that started 12h after interventions (i.e., resting phase in rats), non-
REM sleep and wakefulness were unchanged in all conditions compared to baseline (Fig 3D).
Interestingly, REM sleep was significantly reduced only in the IS group (BL: 10.18% ± 1.30%
vs. post-surgery: 5.35% ± 0.83%, t(5) = 5.35, p = .003; Fig 3D) and increased in the SD_Sham
group (BL: 9.66% ± 0,77% vs. post-surgery: 16.91% ± 3.02%, t(3) = 3.23, p = .04; Fig 3D),
Fig 3. Changes in sleep EEG during the first 24h after interventions. (A) The time line of the experiment. Sleep
was analysed at the baseline before SD and after 24h from either ischemia or sham surgery; 12h dark,12h light
periods. (B) The amount of total sleep (mean ± SEM) is represented by vertical bars. Dark bars indicate the baseline
time, which was defined as the percentage of time spent in each state across 24h of recording baseline. White bars
indicate post-surgery times across 24h after interventions. (C) Total, wake, non-REM and REM sleep (mean ± SEM)
were analysed separately over the dark period. (D) Total, wake, non-REM and REM sleep (mean ± SEM) were
analysed separately over the light period. Comparison with corresponding baselines was performed with paired t-
tests (see S3 and S4 Tables for data set). Stars denote post-surgery times that differed significantly from baseline
time and specific p values are shown. * P .05; **p .01; *** p .001; **** p .0001. Experimental groups: i.
SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv Sham (n = 6).
doi:10.1371/journal.pone.0168430.g003
SD Pre-Ischemia and REM Sleep, MCH and OX Systems
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whereas it was not statistically different in the SD_IS and Sham groups compared to the base-
line (Fig 3D).
In addition, the duration and frequency of REM sleep bouts were assessed during the acute
phase after stroke and sham surgery. The number of short bouts of REM sleep (from 10 to 60
seconds), was markedly reduced in the IS group (two-way ANOVA: F (12, 84) = 2.48 p = .007;
Fig 4A “group×length of the bout” interaction effect) compared to all other groups investigated
and compared to the baseline. Notably, the number of short bouts of REM sleep in the SD_IS
group was not statistically different when compared with the baseline values and with both
sham groups.
Finally, to investigate how sleep and in particular the changes of REM sleep during the
acute phase of ischemia (first 24h after ischemia) influence infarct volume, correlation of REM
sleep with infarct volume was computed. The percentage of REM sleep recorded during the
first 24h after ischemic surgery was negatively correlated with the infarct volume measured in
the 12 rats (n = 6 rats belonging to the SD_IS group and n = 6 rats belonging to the IS group)
which underwent ischemia (Pearson’s R2 = .36, p = .036, Fig 5).
Changes in sleep EEG during 2 and 3 days after interventions. A repeated-measures
analysis of variance revealed a significant effect of time on the total amount of sleep, (F(2, 36) =
3.81, p = .032 “time” Fig 6B), and the same was observed for non-REM sleep (F(2, 36) = 7,49
p = .001 “time” Fig 6C). Conversely a significant interaction between the two factors:
treatment × time was observed for the amount of REM sleep (rANOVA: F(6, 36) = 2.66 p =
.030 Fig 6C). Indeed, REM sleep was increased in both groups, which underwent SD (SD_Sham
and SD_IS groups) at 2 days following interventions compared to IS and Sham groups.
Fig 4. The number and length of bouts of REM sleep. Each number of REM bouts as a function of sleep period length (in seconds) is shown over the
first 24h (A); 2 days (B) and 3 days (C) after interventions; sleep deprivation (SD) and either ischemia and sham surgery and during the baseline time. The
daily number of REM sleep bouts during baseline accounts for the control values (n = 6 baseline values belonging to each animal randomly assigned to the
experimental groups were averaged for each condition). The figure represents the average (±SEM) number of sleep periods of a specific length in the
following experimental groups: i. SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv Sham (n = 6). Statistical analyses were performed by two-way
ANOVA (factors: “group×length of the bout”) and post hoc analysis, with Tukey’s multiple comparison tests run afterward. a: p .01, IS group vs. baseline;
SD_IS, SD_Sham and Sham groups. b: p< .0001, SD_IS group vs. baseline, IS and Sham groups.
doi:10.1371/journal.pone.0168430.g004
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Instead, wakefulness was significantly decreased in the SD_IS group at 2 days relative to IS
and Sham groups (rANOVA: F(6, 36) = 3,41 p = .009 group x time” interaction effect Fig 6C).
The duration and frequency of REM sleep bouts were also assessed at 2 and 3 days after
interventions. Interestingly, the number of short bouts of REM sleep (from 10 to 60 seconds)
was still increased in the SD_IS group (2 days after stroke when compared to the baseline val-
ues, IS and Sham groups, as detected by two-way ANOVA (F (3, 84) = 135, p = .0001 “group”
Fig 4B). At 3 days, the number of REM sleep bouts did not show any statistical differences
between groups (Fig 4C).
Gene expression analysis
To test for an association of MCH and OX gene expression with the protective effect of sleep
deprivation, time course of gene expression of Pmch and OxA and their receptors Mchr1,
Ox1R and Ox2Rwere analysed at 4, 12, 24 hours and at 3, 5, 7 days following ischemia in both
ischemic and contralateral hemispheres (Fig 7A). Both hemispheres were investigated 1) to
confirm that these genes are indeed ischemia-related, and 2) to uncover any potential bilateral
effects. Additionally, a gene expression of Bdnf was performed in all groups investigated at sev-
eral time points, however no differences were found among groups over the time (see S3 Fig).
MCH-system
Time course of precursor of MCH (Pmch). Both groups that underwent ischemia (IS
and SD_IS) showed a significant increase of Pmch during the acute phase of stroke (from 4h to
24h) in both hemispheres compared with the Sham group (see Fig 7B, for relative F values and
p values). Moreover, the Pmch level was still increased exclusively in the SD_IS group in the
lesioned hemisphere at 3 days (F (3, 18) = 5.27, p = .008) and at 5 days (F (2, 15) = 5.61, p =
.01) (Fig 7B). Conversely, the Pmch level declined in the IS group from 24 to 7 days following
ischemia, in both hemispheres, displaying the same level as the Sham group. At 7 days, Pmch
did not differ in either groups or hemispheres (Fig 7B).
Fig 5. Correlation of the amount of total REM sleep phase during the first 24h after ischemic surgery
with the infarct volume assessed at 7 days in 12 rats. REM sleep values as a percentage of total recording
time, including both the light and dark periods (see S5 Table for data set).
doi:10.1371/journal.pone.0168430.g005
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Time course of MCH1 receptor (Mchr1). As observed for Pmch its receptor Mchr1 was
also increased during the acute phase of ischemia (at 4h and 24h following ischemia) in both
groups which, underwent ischemia (IS and SD_IS groups) compared to Sham group. Notably,
Mchr1 was increased in both hemispheres of the SD_IS group (see Fig 7B, for relative F values
and p values) whereas, in the IS group at 24h Mchr1 was significantly increased only in the
lesioned hemisphere (see Fig 7B, for relative F values and p values). Additionally, Mchr1 did
not show any statistical differences between groups at later time points, as was observed for
Pmch.
OX-system
Time course of Orexin (OX)-A/hypocretin-1 (OxA). OxA was increased during the
acute phase of ischemic stroke (at 4h and 24h following ischemia) in both groups which under-
went ischemia in the lesioned hemisphere compared to Sham group (see Fig 7C, for relative
F values and p values), as also observed for Pmch. Notably, the SD_IS group displayed an
increase of OxA over a longer period of time, for 3 days relative to the Sham and IS groups
(F (3, 18) = 6.41, p = .003). At 5 and 7 days OxA did not show any statistical differences
between either groups or hemispheres (Fig 7C).
Time course of Orexin/hypocretin receptor-1 (Ox1R) and receptor-2 (Ox2R). Since
OxA binds the Ox1R and the Ox2R both were assessed to fully understand any involvement
Fig 6. Changes in sleep EEG during the 2 and 3 days after interventions. (A) The timeline of the experiment. Sleep was
analysed at the baseline and over the following 2 and 3 days. The baseline values was given by the percentage of time spent in each
state across 24h of baseline recording. (B) The amount of total sleep (mean ± SEM) for each experimental group at the BL; 2 day and
3 day post-recovery (i. SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv. Sham (n = 6)). Time (baseline, 2 and 3 days) is
displayed in the x-axis. (C) Total, wake, non-REM and REM sleep (mean ± SEM) were analysed separately over the baseline and 2
and 3 days after interventions (see S3 Table for data set). Statistical analyses were performed rANOVA (factors: group and time) and
post hoc analysis, with Tukey’s multiple comparison tests run afterward. Asterisks (*) indicate a statistical difference between groups
(*P .05), whereas dots (˚) indicate a statistical difference between days within the same group (˚˚P .05).
doi:10.1371/journal.pone.0168430.g006
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Fig 7. Time course of gene expression of the precursor of MCH (Pmch) and MCH1 receptor (Mchr1) in the
ischemic and contralateral hemispheres. (A) An example (is at the level of bregma -1.82 mm on the rat brain
atlas by Paxinos and Watson, which accounts for L6) of the six levels of the coronal section of rat brain dissected into
two parts, ischemic and contralateral hemispheres for gene expression analysis by qRT-PCR (see methods for more
detils). The white area in the left hemisphere displays the distribution of ischemic damage in the somatosensory
cortex. (B) Time course of gene expression of Pmch and Mchr1 at several time points (i.e. 4,12 and 24 hours and 3,4
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of OX-system in the neuroprotection of SD. Interestingly, Ox1R was significantly increased
during the acute phase of ischemic stroke in the lesioned hemisphere (at 4h to 24 following
ischemia) in both groups subjected to ischemia relative to the sham group (see Fig 7C, for
relative F values and p values) as already described [34, 35]. Interestingly, this increase was
still observed in the SD.IS group only in the contralateral hemisphere at 5 days following
interventions compared to the Sham and IS groups (see Fig 7C, for relative F values and p
values).
Further, Ox2R showed a significant increase in both hemispheres in SD_IS at a unique and
early time point (4h) relative to the sham group (F (3, 18) = 10.96, p = .001), while in the IS
group this was increased only in the lesioned hemisphere. After this time point Ox2R levels
remained unaltered between either groups or hemispheres over the time (Fig 7C).
Discussion
The main results of this study are consistent with data already published showing that SD pre-
ischemia is neuroprotective. We also observed that SD pre-ischemia animals had a significant
increase of REM sleep during the acute phase of stroke. On the other hand, ischemic animals
showed a significant reduction of REM sleep. Finally, an association between ischemic stroke
and the beneficial effect of SD with an increase in the gene expression of the MCH and OX sys-
tems was found.
Effects of sleep deprivation on infarct volume
This study confirms the neuroprotective effect of SD pre-ischemia 7 days after stroke [11, 12,
24], which is consistent with data observed at 5 days. In addition, these results show that SD
pre-ischemia has a positive effect on infarct volume at 12h. However, this positive effect was
not consistent at 24h and 3 days after interventions. This finding was unexpected, and sug-
gests that SD pre-ischemia induces a delay in infarct volume growth, indicating a beneficial
effect in addition to the main neuroprotective described so far. One possible explanation is
that SD pre-ischemia may prepare the brain to minimize the damage and may promote the
formation of new neurons in the chronic phase. This observation is consistent with the
notion that preconditioning treatments, such as a short ischemic preconditioning, induce
neurogenesis in adult rats’ brains with a maximum peak of cell proliferations after 7 days
[36, 37]. Supporting, this interpretation, there is evidence suggesting that sleep itself pro-
motes the production of new cells and neurons [38] while chronic SD causes a reduction of
hippocampal cell proliferation and neurogenesis, and consequently may impair hippocampal
plasticity and function [39]. Taken together, these data point to the possibility that neurogen-
esis process is also implicated in the neuroprotective effect elicited by SD although in the
present study we did not perform a neurogenesis study based on the administration of BrdU
(5-bromo-2-deoxyuridine)
and 7) after interventions are displayed on the x-axis (see S6 Table for data set). (C) Time course of gene
expression of OxA, Ox1R and Ox2R at several time points (i.e. 4,12 and 24 hours and 3,4 and 7) after interventions
are displayed on the x-axis. Gene expression (mean ± SEM) was assessed by qRT-PCR in rats belonging to the 4
experimental groups: i. SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv Sham (n = 6). Gapdh was used as the
reference gene. The ΔΔCt method was used to determine the fold change in gene expression. Statistical analysis
was performed by one-way ANOVA (see F values and p values) and post hoc analysis with Tukey’s multiple
comparison test was run afterwards. a: p< 05 when compared to sham group; b: p< 05 when compared to IS group;
c: p< 05 when compared to SD_IS group and d: p< 05 when compared to SD_Sham group.
doi:10.1371/journal.pone.0168430.g007
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Alteration in the sleep-wake cycle architecture after ischemia
Our data also confirm that SD pre-ischemia induces a significant increase in the amount of
total sleep during the first 24h after ischemia, an effect that persists for 2 days in the SD_IS
group following ischemic stroke.
Furthermore, our observations indicate that non-REM sleep also increases during the acute
phase of ischemic stroke in all conditions tested, independently of animal treatment, indicating
that the early increase of non-REM is not related to an ischemic event or SD treatment, but
rather a response to surgical procedures since the ischemic model that we used requires a
small craniotomy and/or anesthesia. This observation is consistent with others studies that
noticed an effect of isoflurane on sleep homeostasis [40] and non-REM-like EEG activity dom-
inated by slow waves [41]. On the other hand, at 2 days following interventions, non-REM
sleep was found to be increased in the SD pre-ischemia animals, and not in other groups inves-
tigated including the SD_Sham group. These results suggest that this increase of non-REM
sleep at 2 days is not related to SD intervention but rather to an effect of the SD as the precon-
ditioning effect that should be clarified in the future. Indeed, there are studies at supporting
the fact that non-REM sleep is a good predictor of favourable outcomes after hemispheric
ischemia [17, 18].
Conversely, REM sleep was differently modulated among all conditions from the early
phase of ischemic stroke until 2 days after interventions. Indeed, as observed by Mashour and
collaborators, 4h of isoflurane anaesthesia does not affect the REM sleep rebound after selec-
tive REM sleep deprivation for 24h [42]. Specifically, REM sleep was significantly increased in
both groups subjected to SD interventions (SD.IS and SD_Sham groups,) suggesting, that the
increases in the intensity of REM sleep, as well as the number of short REM sleep bouts, are
related to the extent of sleep deprivation and represent a homeostatic recovery response [43].
Conversely, ischemia animals that did not undergo SD showed a marked decrease of REM
sleep as already described previously in both humans and animals [21, 22]. These results sup-
port the idea that the increase in the amount of total sleep and particularly the increase of
REM sleep during the acute phase of ischemic stroke are induced by previous SD interven-
tions. We suggest that SD pre-ischemia may facilitate the transition from non-REM to REM
sleep, probably because the need for sleep increases after previous SD treatment. According to
the metabolic hypothesis of sleep, [44], it is possible that sleep change after stroke results from
a metabolic recovery of energy stores.
In addition, this study demonstrates that in the early phase of stroke, the increase of
REM sleep is negatively correlated with infarct volume assessed after 7 days from ischemic
stroke, which suggests a potential role of REM sleep in the neuroprotective effect of SD pre-
ischemia. However, the increase of REM sleep in SD pre-ischemia animals might be related
to other factors such as reduced inflammation and low level of cytokines in the brains of SD
animals [14, 24]. Indeed, REM sleep is particularly influenced by several inflammatory
mediators such as cytokines [45, 46], and it has been shown that inflammation strongly
exacerbates brain damage in ischemic pathophysiology [47]. Nevertheless, some other
mediators like adenosine, which has been described to play a crucial role in the acute pre-
conditioning [48], maybe also implicated in the neuroprotective effect elicited by SD.
Although we did not measure adenosine in our study, a body of evidence describe that aden-
osine plays a role in sleep control [49], and particular the adenosine A1 receptor has been
found to be increased following SD in humans [50] and animals [51]. Thus, adenosine influ-
ences a set of pathophysiological processes involved in the ischemic stroke, and for some
time adenosine and its receptors have been viewed as potential therapeutic targets for the
treatment of stroke [48].
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Association of melanin-concentrating hormone (MCH) and Orexin/
Hypocretin with the pathophysiology of ischaemic stroke
In the present study, the expression of MCH and OX systems were significantly increased dur-
ing the acute phase of ischemia (12h and 24h) in both groups that underwent ischemia regard-
less of SD intervention, indicating that ischemia itself induces the increase of both systems.
This data shows that SD pre-ischemia may influence the gene expression of MCH and OX sys-
tems for a long period of time (up to 5 days following ischemic stroke). Taken together, these
results provide substantial evidence that enables us to consider that these systems are associ-
ated with ischemic stroke as well as with the beneficial effect of SD pre-ischemia. In addition,
we found that MCH and OX systems were increased in both hemispheres in the acute phase of
stroke. This suggests that at early time points the increase of MCH and OX systems were influ-
enced bilaterally i.e. their expression may be modulated by devastating events occurring in the
ischemic hemisphere that also influences the contralateral hemisphere. On the contrary, at the
late time points their expression are ischemia-related since they were increased exclusively in
the ischemic hemisphere.
Our hypothesis regarding the association of these two systems with ischemic stroke is sup-
ported by a recent series of clinical and experimental studies describing the involvement of OX-
system in post-ischemic stroke. A clinical study on patients with cerebral infarction showed a
persistent decrease of cerebrospinal OXA concentrations [52]. Consistent with this finding our
results and published experimental studies [34, 53] show that ischemic stroke induces increased
expression of Ox1R in the brain, which correlates with decreases of OXA in cerebrospinal fluid
as an adaptive response to maintain OXA supply to the brain. Finally, a recent study showed
that in some conditions such ischemic stroke, cortical neurons may homeostatically switch to
the production of OXA as an adaptation mechanism [54]. This observation is consistent with
the notion that re-mapping processes that spontaneously occur after stroke [55, 56] may induce
an early change of genes expression, and OX and MCH systems may be involved in this process.
However, the mechanism of both the OX and MCH systems in the pathophysiology of
ischemic stroke, remain poorly understood and most likely involve inflammation and metabo-
lism systems instead of sleep-wake cycle regulation. Indeed, consistent with our speculation
there is a series of studies which have observed that MCH and OX neurons are affected by
inflammation, showing a decline when injected with bacterial lipopolysaccharide, which is
extensively used to mimic many inflammatory effects of cytokines [57, 58]. It is possible that
the increase of both MCH and OX systems in the SD_IS group up until 3 days and 5 days fol-
lowing ischemia may be related to inflammation, which is supposed to be attenuated, com-
pared to IS group alone [14, 24]. Moreover, a study showed that subsets of CD4 (+) T-helper
cells in vivo are able to selectively express Pmch [59], which has been known to play a central
role in the pathophysiology of ischemic stroke [60].
Taken together, these data point out the possibility that inflammation or metabolic system
are the key elements of action of MCH and OX systems [25, 61–63] in the pathophysiology of
ischemic stroke as well as in the beneficial effect of SD intervention.
Strengths, limitations and approaches for future research
This study provides direct evidence that SD pre-ischemia induces a delay in infarct volume
growth and that neurogenesis is probably involved. Moreover, we conclude that REM sleep
may play a role in neuroprotection, and consequently may facilitate functional recovery after
ischemic stroke [12]. To test this hypothesis, we used animals subjected to SD pre-ischemia,
which showed an increase of REM sleep as homeostatic sleep response given by previous SD
intervention, not inducted artificially by drugs.
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One of the limitations of this study is that we only assessed the changes in the mRNA gene
expression of the MCH and OX systems, although, it is well established that many post-tran-
scriptional regulations interfere with the level of active protein.
Altogether, these findings provide the basis for further research to understand the role of the
MCH system in ischemic stroke and whether MCH also has a neuroprotective effect. Further, to
better understand the role of the REM sleep stage in ischemia; a pharmacological treatment with
MCH agonists should be performed to prolong REM during the acute phase of stroke, conversely
selective REM sleep deprivation should also be performed during the acute phase of stroke.
Conclusion
Our data indicates that REM sleep may be involved in the neuroprotective effect of SD pre-
ischemia, and that both, MCH and orexin systems are increased during the acute phase of
stroke. Future studies should assess the role of REM sleep as a prognostic marker, and test
MCH and OXA agonists as new treatment options in the acute phase of stroke.
Supporting Information
S1 Fig. (A) Not-to-scale representation of the placement of the screw electrodes over the parietal
cortex and the cerebellar cortex (pink circles), Ref. = reference and EEG = electroencephalogram.
EMG (electromyogram) in grey was bilaterally placed in the neck muscle using wire electrodes
(B) An example of the homemade-plug used to record EEG/EMG fixed on the head of the ani-
mal. (C) An example showing how rats were maintained during the EEG/EMG recording. Rats
were housed individually in their home cages and then each rat was connected to a flexible cable
and swivel (Plastics One) that allowed free movement within the chambers.
(TIF)
S2 Fig. Effects of sleep deprivation (SD) pre-ischemia preconditioning on the infarct vol-
ume. Lesion volumes uncorrected for edema were calculated by cresyl violet staining at 12 and
24 hours and 3, 5 and 7 days after ischemic surgery are displayed on the x-axis. Infarct volume
uncorrected for edema was assessed by multiplying the infarcted area by the slice thickness
and combining the volume of the six slices (see methods). Infarct volume (mean ± SEM) were
analysed by unpaired t-test (n = 6 per group). Dots represent the infarct volume of each animal
during each time point. Asterisks () indicate a statistical difference between groups, p .01;
 p .001. These results are consistent with the data shown in the Fig 2 where infarct size
was corrected for edema. However, lesion size without correction for edema is overestimated
by almost 30% at 24 h and by 20% at 12h of MCAo.
(TIF)
S3 Fig. Time course of gene expression of Brain-derived neurotrophic factor (Bdnf) in
the ischemic and contralateral hemispheres. Time course of gene expression of Bdnf at sev-
eral time points (i.e. 4,12 and 24 hours and 3,4 and 7) after interventions are displayed on the
x-axis. Gene expression (mean ± SEM) was assessed by qRT-PCR in rats belonging to the 4
experimental groups: i. SD_IS (n = 6); ii. IS (n = 6); iii. SD_Sham (n = 4); and iv. Sham
(n = 6). Gapdh was used as the reference gene. The ΔΔCt method was used to determine the
fold change in gene expression. Statistical analysis performed by one-way ANOVA did not
show any significant changes in the Bdnf mRNA expression between groups, and in both
hemispheres, at all time points investigated.
(TIF)
S1 Table. Data set of the infarct values volume assessed for each animal belonging to the
Ischemia group and SD_Ischemia group at several time points (i.e 12h, 24h, 3-5-7 days
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after interventions).
(DOCX)
S2 Table. Data set values used to calculate the infarct volume with and without correction
for edema.
(XLS)
S3 Table. Data set of the EEG sleep recording values obtained during the 24 of baseline
and after 24 (dark and light phase) 2 and 3 days interventions, for each animal investigated
belonging to the 4 experimental groups.
(DOCX)
S4 Table. Data set of values obtained from the EEG sleep recording expressed as hourly
percentage time spent in wakefulness, total amount of sleep (including both non-REM
sleep and REM sleep), and non-REM and REM sleep separately across the 24h of baseline
(BL) and for the following three days after surgery, for each animal investigated belonging
to the 4 experimental groups.
(XLSX)
S5 Table. Data set of the values used to make a correlation between the amount of total
REM sleep phase during the first 24h after ischemic surgery with the infarct volume
assessed at 7 days in 12 rats.
(DOCX)
S6 Table. Data set relative to the gene expression of melanin concentrating hormone
(MCH) and orexin-A (OXA) obteined from the ipsilateral and contralateral hemispheres
at several time points (i.e 12h, 24h, 3-5-7 days after interventions), in each animal belong-
ing to the 4 experimental groups (Ischemia; SD_Ischemia; Sham and SD_Sham groups).
(DOCX)
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